Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-2118 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intratumoral, Subcutaneous, Intravenous
01
Overview
**MK-2118 + pembrolizumab** is a combination investigational therapy composed of MK-2118, a noncyclic dinucleotide small molecule agonist of the stimulator of interferon genes (STING) pathway, and pembrolizumab (Keytruda), a monoclonal antibody checkpoint inhibitor targeting programmed cell death protein 1 (PD-1). MK-2118 is designed to activate the innate immune response via induction of type I interferon and proinflammatory cytokines through STING pathway activation. Pembrolizumab enhances the immune system’s ability to recognize and attack tumor cells by blocking PD-1, thereby preventing its interaction with PD-L1/L2 and reversing T-cell suppression. The combination has been evaluated in a Phase 1 trial for the treatment of advanced/metastatic solid tumors and lymphomas using intratumoral or subcutaneous MK-2118 administration in combination with intravenous pembrolizumab. This approach aims to synergistically increase anti-tumor immunity, potentially overcoming resistance to checkpoint inhibitors[1][2][3].
- Other names
- MK-2118 + pembrolizumab
02
Targets
STING (Stimulator of interferon genes protein)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on MK-2118 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-2118 + pembrolizumab.